entertainment -WSS

entertainment

author：Wikipedia 2025-08-11 08:01:03 - browse：363

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

focus

WSS

Medicare Advantage overpayments discussion gets experts fired up

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

What to do when lifesaving products contribute to climate change

With clinical trial data readouts, here's how to spot spin

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

focus

entertainment

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

BIO selects John Crowley as new CEO

At least 13 dead in Texas as scorching temps continue

Medicare Advantage overpayments discussion gets experts fired up

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Hollywood unions extend contract negotiations for actors

Merck to acquire Harpoon Therapeutics for $680 million

In age of alternative facts, a scholarly course on calling out crap

Takeda, Janssen join wearable maker to measure scratching

focus

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

In shift, Texas to cover initial consult for Afghan baby's gene therapy

U.K. Biobank has 500,000 peoples' genome sequences available

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Takeda, Janssen join wearable maker to measure scratching

30 years of 'Listening to Prozac'

leisure time

focus

hotspot

Wikipedia